OBJECTIVEWeinvestigatedwhetherthe antiproteinuric effectof the directrenininhibitoraliskiren is comparable to that of irbesartan and the effect of the combination.
Novartis announced today the early termination of the ALTITUDE trial, which was testing the effect of the directrenininhibitor aliskiren (Rasilez, Tekturna) in type 2 diabetics at high risk for cardiovascular and renal events.